Navigation Links
Trans fatty acids increase the risk of gallstone,,disease.

Several studies have shown that consumption of trans fatty acids leads to development of diabetes, cancer and cardiovascular disease.// Trans fatty acids are the hydrogenated and partially hydrogenated oil present in some margarines, candies, baked goods and many processed foods. They are produced commercially in large quantities by heating vegetable oils in the presence of metal catalysts and in the process the poly unsaturated fatty acids are removed. Trans fatty acids increase LDL cholesterol (the bad cholesterol) and decrease HDL cholesterol (the good cholesterol )thereby increasing the risk of heart disease.

A prospective study published in the May issue of the Archives of Internal Medicine has shown that higher consumption of trans fatty acids increased the risk of gallstone disease. The study was performed by applying a semi quantitative questionnaire that had questions relating to the food and frequency of food intake to a cohort of nearly 46000 men twice a year. Patients diagnosed with gallstone disease based on the X ray and cholecystectomy findings were recorded. During 14 years of follow-up, 2356 new cases of patients with symptoms who had gallstones were recorded. The result which was adjusted for difference in age and other associated risk factors showed that those men who had taken higher amounts trans fatty acids had a greater relative risk(1.23) of gallstone diseases compared with those who had taken lower amounts. Among the subtypes of trans fatty acids risk was more with trans-oleic fatty acid as compared to the other types. Intake of the unsaturated vegetable oils from canola, peanuts, olive, flax, corn, safflower and sunflower which contain monounsaturated or polyunsaturated fatty acids that can reduce total cholesterol and increase HDL cholesterol levels assumes significant importance in this context. So play it safe by eating safe.

Reference
Arch Intern Med. 2005;165:997-10
'"/>




Page: 1 2

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
3. Stem Cell Transplants May Be Effective For MS Patients
4. Transforming stem cells to lung cells
5. Alternative to blood Transfusions
6. Need for Blood Transfusions reduced
7. Drugs Deter Heart Disease for Transplant Patients
8. Better Drug for Heart Transplant
9. Kidney Failure after Non-Kidney Transplants
10. Measles Risk in Transplant Patients
11. West Nile and Blood Transfusions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Trans fatty acids increase the risk gallstone disease

(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... the cause, experts say , , THURSDAY, Jan. 22 (HealthDay News) ... are dying at twice the rate they were a few ... , The report, led by the U.S. Geological Survey (USGS), ... in a variety of forests, elevations and sizes. Species have ...
... brain tumors affect nearly 20,000 Americans each yearand every ... For young adults ages 30-39, brain tumors are the ... among women. Despite significant advances in cancer treatment, ... brain tumor, survive roughly 12 to 14 months post ...
... Ali Rashidee Will Serve as Co-Chair for the PSSIG ... /PRNewswire/ -- Dr. Ali Rashidee, Quantros ... Co-Chair for the HL7 Patient Safety Special Interest Group ... the implementation of interfaces between health care applications for ...
... The Association for Professionals in Infection Control ... Targeting Zer o initiative for 2009 to offer ... common and fatal healthcare-associated infections (HAIs). Targeting ... such as HAI elimination guides. APIC,s evidence-based elimination ...
... Delaney, the founder and longtime director of the HIV ... National Institute of Allergy and Infectious Diseases (NIAID) Director,s ... fight against HIV/AIDS. , Mr. Delaney in ... and public policy information and advocacy organization based in ...
... but some experts are skeptical , , THURSDAY, Jan. 22 ... on the common assumption smokers have that their unhealthy ... found that teens who smoke heavily were more likely ... no evidence that cigarettes directly cause obesity, but "this ...
Cached Medicine News:Health News:Old-Growth Forests Dying Off in U.S. West 2Health News:Old-Growth Forests Dying Off in U.S. West 3Health News:New institute targets brain tumor removal 2Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 2Health News:Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7 3Health News:APIC 2009 'Targeting Zero' Initiative Offers Practical Tools, Evidence-Based Elimination Strategies to Prevent the Deadliest Healthcare-Associated Infections 2Health News:APIC 2009 'Targeting Zero' Initiative Offers Practical Tools, Evidence-Based Elimination Strategies to Prevent the Deadliest Healthcare-Associated Infections 3Health News:NIAID honors AIDS activist Martin Delaney 2Health News:Heavy Smoking as Teenager Might Add Pounds Later 2
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, ... delighted to announce that the Malcolm Campbell Memorial ... (Vice President of Chemistry), Fiona Marshall (Chief ... Executive Officer and co-founder) for the seminal contributions to GPCR ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
... A new Transnasal Lacrimal Stent has been introduced ... Becker, M.D., the Transnasal Lacrimal Stent addressed the ... other forms of endoscopic DCR. Brought in to ... large diameter. Because there is no need to ...
... With the OrthoPilot, physicians now have a ... interventions. , ,The only platform you ... a complete, cost-effective system requiring little space. ... new applications make OrthoPilot a strong and ...
... Field Analyzer II-i series is a wheelchair ... patient's visual field. ,By using SITA, the ... reduced by up to 70%. ,A patented ... design to increase patient comfort while testing ...
... is an innovative device designed to be ... with abdominal aortic aneurysms (AAA). It is ... with an outer self-expanding Nitinol support structure ... durability. The function of the endoprosthesis is ...
Medicine Products: